Moderna (MRNA) - P/S ratio

P/S ratio as of November 2026 (TTM): 40.7

According to Moderna 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 13.3. At the end of 2026 the company had a P/S ratio of 12.1.

P/S ratio history for Moderna from 2018 to 2026

PS ratio at the end of each year

Year	P/S ratio	Change
2026	12.1	92.51%
2025	6.27	29.96%
2024	4.83	-14.02%
2023	5.61	53.56%
2022	3.66	-37.03%
2021	5.81	-96.15%
2020	151	9.95%
2019	137	235.08%
2018	40.9

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Johnson & Johnson JNJ	6.62	-83.74%	🇺🇸 USA
Novartis NVS	5.37	-86.80%	🇨🇭 Switzerland
Merck MRK	5.52	-86.45%	🇺🇸 USA
Regulus Therapeutics RGLS	N/A	N/A	🇺🇸 USA
Dicerna Pharmaceuticals DRNA	N/A	N/A	🇺🇸 USA
Athersys ATHX	10.4	-74.43%	🇺🇸 USA
Alnylam Pharmaceuticals ALNY	4.49	-88.96%	🇺🇸 USA
Arrowhead Pharmaceuticals ARWR	12.5	-69.22%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Moderna (MRNA)

P/S ratio as of November 2026 (TTM): 40.7